Hi Foxtra - the latest information I can find on the Phase lll trial is on the AVX website in a press release to the Biotech Daily dated Wednesday June 25th, 2014. It quotes $30m for a 300 patient Phaselll trial and states that sufficient stocks of ATC are held for the Named Patient Scheme and the trial. Be nice to see some action.
Cheers